Ra’anana-based company specializes in the development and application of advanced trans-membranal drug delivery formulation solutions. Seeking introductions to strategic partners, pharma companies, medical research institutions and investors.
The basic drug delivery system, based on a micro-emulsion technology, was originally developed at Ben Gurion University of the Negev, Beer Sheva. During the past four years the Company has developed a new advanced safe, painless and cutting-edge platform.
The Company’s proposed technology consists of Self-Assembled Nano-structural System (SANS) (Ø=10-50nm) for drug delivery or SANS-based Drug Delivery Technology (SANS- DDT) comprising of a versatile, bio-compatible, isotropic, thermodynamically stable drug delivery system made of pharmaceutical grade ingredients (GRAS). Management believes that the Company’s SANS offers an appropriate drug delivery system also for new and emerging biotechnology derived products. It will enable non-parenteral/needle-free delivery of biopharmaceuticals that are presently administered subcutaneously (e.g. insulin injection) and other medications that transdermal delivery would improve their efficacy but are not permeable through the skin.
The Company is currently engaged in three developments:
1. Continuous Transdermal L-DOPA/Carbidopa Therapy for Parkinson’s Disease (Patch); The Company’s approach may provide a clinically effective transdermal delivery of levodopa for the treatment of Parkinson’s disease and to eventually achieve a simple solution for the late motor complications. According to the Parkinson’s Disease Foundation, there are around one million Americans suffering from Parkinson’s disease, and 60,000 new patients are diagnosed each year. Medication costs are estimated to be around $2,500 per person each year, with a total economic impact of around $25 billion in the U.S. alone.
2. Nasal Administration of Parathyroid Hormone; Parathyroid hormone (PTH) is naturally an 84-amino-acid polypeptide. Attempts to develop a drug based on the recombinant molecule rhPTH1-84, which have been unsuccessful so far. In 2002 the FDA approved teriparatide, PTH 1-34, of recombinant DNA origin, manufactured by made by Eli Lilly with the brand name FORTEOTM (injectable). Based on the animal studies carried out by the Company, Management believes that the Company may possibly develop a nasal delivery of the PTH 1-34 peptides using the SANS.
3. Intranasal Insulin Delivery;
The Company has obtained, in a series of pharmacokinetics and pharmacodynamics studies in diabetic (chemically induced) rabbits; approximately 20% relative bioavailability was obtained by intranasal administration of nano-sized emulsion (compared with the conventional subcutaneous administration). The percentages of bioavailability obtained were, to the best of our knowledge, significantly higher values than any value published in the literature thus far. In recent experiments with a new formulation of SANS we have succeeded to further increase the bioavailability of insulin in the rabbit model (unpublished data).